Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial.
暂无分享，去创建一个
A. Keech | R. Giugliano | M. Sabatine | S. Murphy | J. Jukema | P. Sever | Z. Gaciong | S. Wiviott | R. Češka | T. Pedersen | N. Honarpour | C. Kurtz | K. Toth | M. Tikkanen | M. Ezhov | K. Im | D. Connolly | K. Tóth | Narimon Honarpour